Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.69 |
| ▸ | ACE | P12821 | 1/20 | 0.65 |
| ▸ | PPARG | P37231 | 4/20 | 0.64 |
| ▸ | CTSS | P25774 | 5/20 | 0.61 |
| ▸ | CTSK | P43235 | 3/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL3925161 | 0.93 | CTSS (0.70) | PPARAACEPPARGCTSSCTSK | |
| Benzene SCHEMBL6474758 | 0.93 | CTSS (0.70) | PPARAACEPPARGCTSSCTSK | |
| SCHEMBL231980 | 0.91 | CTSS (0.71) | PPARAACEPPARGCTSSCTSK | |
| SCHEMBL1310547 | 0.91 | CTSS (0.71) | PPARAACEPPARGCTSSCTSK | |
| SCHEMBL231981 | 0.91 | CTSS (0.71) | PPARAACEPPARGCTSSCTSK | |
| SCHEMBL29824479 | 0.91 | CTSS (0.68) | PPARAACEPPARGCTSSCTSK | |
| SCHEMBL606309 | 0.89 | ACE (0.79) | PPARAACEPPARGCTSSCTSK | |
| SCHEMBL21473784 | 0.89 | ACE (0.79) | PPARAACEPPARGCTSSCTSK | |
| SCHEMBL67020 | 0.89 | ACE (0.79) | PPARAACEPPARGCTSSCTSK | |
| SCHEMBL66220 | 0.89 | ACE (0.79) | PPARAACEPPARGCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44186-E1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| US-6395767-B2 | ANTIDIABETIC AGENTS; SAXAGLIPTIN | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-28 | — | — | US | disclosed |
| US-20020019411-A1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019411-A1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | DPP4, DPP3, DPP7 | PPARA 292/4885ACE 565/4885PPARG 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.